FOLFIRINOX <i>vs</i> gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

Abstract

Treatment efficacy and economic burdens were comparable between the two regimens. But, the details of adverse event were different. Gem + nabPTX regimen might be considered preferentially in certain conditions.